• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

Recent Advances in the Study of 4-Nitropyridine-3-Carbonitrile (CAS: 1003711-76-9) in Chemical Biology and Pharmaceutical Research

4-Nitropyridine-3-carbonitrile (CAS: 1003711-76-9) is a heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, characterized by its nitropyridine core and carbonitrile functional group, serves as a key intermediate in the synthesis of various bioactive molecules. Recent studies have explored its potential as a building block for drug discovery, particularly in the development of kinase inhibitors and antimicrobial agents. This research brief aims to summarize the latest findings related to 4-nitropyridine-3-carbonitrile, highlighting its synthetic utility, biological activities, and potential therapeutic applications.

One of the most notable advancements in the study of 4-nitropyridine-3-carbonitrile is its role in the synthesis of kinase inhibitors. Kinases are critical targets in cancer therapy, and the nitropyridine scaffold has been leveraged to design potent and selective inhibitors. Recent publications have demonstrated that derivatives of 4-nitropyridine-3-carbonitrile exhibit promising inhibitory activity against specific kinases, such as EGFR and VEGFR, which are implicated in tumor growth and angiogenesis. These findings underscore the compound's potential as a starting point for the development of novel anticancer agents.

In addition to its applications in oncology, 4-nitropyridine-3-carbonitrile has also been investigated for its antimicrobial properties. A 2023 study published in the Journal of Medicinal Chemistry reported that nitropyridine-based compounds, including 4-nitropyridine-3-carbonitrile derivatives, displayed broad-spectrum activity against resistant bacterial strains. The study highlighted the compound's ability to disrupt bacterial cell wall synthesis, making it a promising candidate for addressing the global challenge of antibiotic resistance. Further optimization of these derivatives could lead to the discovery of new classes of antibiotics.

The synthetic versatility of 4-nitropyridine-3-carbonitrile has also been a focal point of recent research. Advances in catalytic methods, such as transition-metal-catalyzed cross-coupling reactions, have enabled the efficient functionalization of the nitropyridine core. For instance, a 2022 study in Organic Letters detailed a palladium-catalyzed cyanation reaction that utilized 4-nitropyridine-3-carbonitrile as a precursor to generate highly functionalized pyridine derivatives. These synthetic methodologies not only expand the chemical space accessible to researchers but also facilitate the rapid exploration of structure-activity relationships in drug discovery.

Despite these promising developments, challenges remain in the practical application of 4-nitropyridine-3-carbonitrile. Issues such as solubility, stability, and bioavailability must be addressed to translate laboratory findings into clinically viable therapeutics. Recent efforts have focused on prodrug strategies and formulation technologies to overcome these limitations. For example, a 2023 patent application described a nanoparticle-based delivery system designed to enhance the bioavailability of nitropyridine derivatives, including 4-nitropyridine-3-carbonitrile, in preclinical models.

In conclusion, 4-nitropyridine-3-carbonitrile (CAS: 1003711-76-9) represents a valuable scaffold in chemical biology and pharmaceutical research. Its diverse applications in kinase inhibition, antimicrobial therapy, and synthetic chemistry highlight its potential to address unmet medical needs. Ongoing research efforts are expected to further elucidate its mechanisms of action and optimize its pharmacological properties, paving the way for its integration into next-generation therapeutics. This brief underscores the importance of continued investment in the study of this compound and its derivatives to unlock their full potential in medicine.

• 89-58-7(2,5-Dimethylnitrobenzene)
• 610-66-2(2-Nitrobenzylcyanide)
• 611-05-2(3-Methyl-4-nitroaniline)
• 607-32-9(5-Nitroisoquinoline)
• 603-83-8(2-methyl-3-nitro-aniline)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)